MENU
NEUP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Neuphoria Therapeutics (NEUP) Ownership - Who owns Neuphoria Therapeutics?
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
17.56M
P/E Ratio
0.47
Total Cash
4.34M
Projected Growth
N/A
Total Debt
199.4K
Revenue
662.72K
Risk (Beta)
0.34
Dividend Yield
N/A
Total Cash/Share
2.47
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
NEUP
Capitalization
17.6M
P/E Ratio
0.47
Risk (Beta)
0.34
Dividend Yield
N/A
Total Cash
4.35M
Total Cash/Share
2.47
Total Debt
199K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
663K
ROE
N/A
Book Value
13.7M
P/B Ratio
0.66
Cash Flow
N/A
Earnings
10.93
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
16
Current Ratio
2.06
Current Revenue Per Employee
27613.13
Dividends Per Share - Security
N/A
EBITDA
-14.17M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-36.80
Shares Held By Institutions
360K
Shares Outstanding - Current
1.76M
Total Liabilities
4.42M
Total Volume MTD
N/A
Value
-1
Gain YTD
51.312
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information